SUMMER 2017
Page 1 to 8 of 8 |
Tackling multi-drug resistant bacteria By Dr Ankit Mahadevia
Antibiotic resistance never should have become the public health crisis we are seeing today. As a society, we thought the problem of bacterial infections had been solved decades ago when more than 200 powerful antibiotics representing different classes such as -lactam, tetracyclines and macrolides were developed.

Read More

Advancing the drug discovery pipeline with early stage In vitro ADME and toxicity testing By Dr Maureen Bunger
With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its standard processes and procedures are as streamlined and effective as possible.

Read More

Long-read sequencing offers path to more accurate drug metabolism profiles By Dr Jenny Ekholm
In the complex drug discovery process, one of the looming questions for any new compound is how it will be metabolised in a human body. While there are several methods for evaluating this, one of the most common involves CYP2D6, the enzyme encoded by the cytochrome P450-2D6 gene.

Read More

New approaches to sample identification tracking and technologies for maintaining the quality of stored samples By Dr John Comley
Safeguarding the quality of stored samples (both compounds and biospecimens) must be the driving ethos in compound management stores and biorepositories.

Read More

Raising the bar on the biologics potential Dr Michael Mouradian
In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment.

Read More

The rise of immunotherapies - strategies to accelerate their advance into clinical trials By Edward Cribb
The striking rise of immunotherapies in the past decade has had a transformative effect on cancer treatment. Also referred to as biologic therapies, immunotherapies are a new class of drug that harnesses the potential of the body's immune system to target and destroy tumours.

Read More

UX Design maximising the value of scientific software in life science R&D By Dr Jennifer Cham & Katrina Costa
Using scientific software can be frustrating and time-consuming, resulting in less productive research. This article aims to demonstrate that User Experience (UX) Design offers specific efficiency benefits for life science R&D.

Read More

The importance of heterocyclic compounds in anti-cancer drug design By Simon Pearce
Heterocycles are key structural components of many of the anti-cancer drugs available on the market today. Indeed, of the novel molecular anti-cancer agents approved by the FDA between 2010 and 2015, almost two-thirds contained heterocyclic rings within their structures.

Read More

SUMMER 2017
Page 1 to 8 of 8 |